Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

CollPlant Biotechnologies Ltd. Sponsored ADR CLGN

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
7.71
Revenue
0.39
Net Income
(13.13)
Free Cash Flow
(11.33)
Net Debt
(4.63)
Current Ratio
2.27
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
16.11
P/B ratio
1.28
Past 5Y EPS Growth
8.32%
This Y EPS Growth
35.10%
Next Y EPS Growth
69.24%
Next 5Y EPS Growth
43.71%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 26.92 12.16 5.95 4.63
Receivables 0.39 0.58 0.22 0.23
Inventory 0.71 0.44 0.57 0.68
Other — — — —
28.02 13.18 6.75 5.54
2023 2024 2025 Q'26
Payables 0.98 0.87 0.61 0.64
ST’ Debt — — — —
Other — — — —
3.25 2.97 2.67 2.44
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 0.07 — — —
—
’25 2.06 0.18 0.08 0.06
2.37
’24 0.10 0.25 0.00 0.16
0.52
’23 0.43 10.18 0.04 0.30
10.96
’22 0.07 0.07 0.11 0.06
0.30
’21 14.50 0.69 0.14 0.31
15.64
’20 0.61 0.82 4.15 0.56
6.14
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (3.05) — — —
—
’25 (1.17) (2.44) (2.88) (2.93)
(9.42)
’24 (3.25) (3.93) (3.45) (3.46)
(14.09)
’23 (3.45) (3.74) 6.78 (2.34)
(2.76)
’22 (3.21) (3.95) (3.18) (3.35)
(13.70)
’21 11.12 (3.38) (2.82) (2.42)
2.50
’20 (2.58) (1.76) 1.49 (1.60)
(4.45)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (3.05) — — —
—
’25 (1.17) (2.44) (2.88) (2.95)
(9.45)
’24 (3.33) (4.13) (3.59) (3.52)
(14.57)
’23 (3.59) (4.08) 6.53 (2.51)
(3.65)
’22 (3.51) (4.34) (3.51) (3.65)
(15.01)
’21 10.94 (3.65) (3.45) (2.89)
0.95
’20 (2.67) (1.92) 1.36 (1.74)
(4.97)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (2.30) — — —
—
’25 (1.30) (2.80) (2.70) (6.70)
(9.40)
’24 (3.70) (3.70) (3.80) (3.40)
(14.50)
’23 (3.30) 4.90 (3.80) (4.20)
(6.20)
’22 (3.60) (3.90) (4.00) (3.90)
(15.30)
’21 8.80 (3.00) (2.90) (3.00)
0.20
’20 (2.40) (2.80) 0.70 (4.20)
(8.40)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 42.70 47.00 32.40 13.00 — — —
Low Price
— — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 168.20 139.70 67.50 49.80 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 73 75 57 39 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.15 0.01 0.06 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.30 10.96 0.52 2.37 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (33.78%) 81.83% (215.53%) 64.78% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.92) (7.02) (16.61) (11.49) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5,660.54%) (64.05%) (3,225.05%) (484.56%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.92) (7.02) (16.61) (11.49) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.08 1.10 1.04 0.91 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.27 9.62 0.45 1.94 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡ (15.30) (6.20) (14.50) (9.40) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (12.42) (2.43) (12.30) (7.72) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.19) (0.78) (0.42) (0.02) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (13.61) (3.20) (12.72) (7.74) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 29.26 24.88 11.76 4.98 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.10 1.14 1.15 1.22 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 317.34 6.29 80.07 7.21 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.94 2.43 3.06 2.81 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 227.82 4.14 62.96 6.11 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.54) (12.28) (2.22) (1.53) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (13.70) (2.76) (14.09) (9.42) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.32) (0.89) (0.48) (0.03) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.01) (3.65) (14.57) (9.45) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.55 24.77 10.21 4.08 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.91 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (26.76) (26.91) (12.16) (5.95) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 32.28 28.34 13.47 6.08 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (38.04%) (19.53%) (62.87%) (77.90%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (193.72%) (329.47%) (824.30%) (5,478.53%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (43.73%) (23.16%) (79.46%) (117.56%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

CollPlant Biotechnologies (CLGN), a leader in plant-based rhCollagen for regenerative medicine and 3D bioprinting, trades at depressed levels after shedding 95% from its 2021 peaks, yet analysts unanimously forecast over 1,500% upside. This valuation disconnect mirrors classic biotech cycles of volatile revenues, ongoing losses, and clinical promise, driven by key partnerships like AbbVie’s dermal fillers deal and the U.S. Navy’s 3D tissue contract, alongside FDA Breakthrough Designations for wound care and BioInks.

Revenue swings epitomize the lumpy milestone model: explosive growth to $15.6 million in 2021, 98% plunges in 2022 and 2024, with a 3,566% rebound in 2023. Forecasts signal a turnaround—$13.6 million in 2025 surging to $36.9 million by 2027—potentially validating high-margin scalability (90%+ at volume), though profitability remains elusive amid cash burn and negative margins, with breakeven eyed post-2027.

A cash-rich balance sheet offers runway despite dilution and ROE weakness, while EV/Sales multiples scream undervaluation on forward growth. Risks abound—trial failures, biotech winter—but catalysts like deal expansions could ignite a rebound, echoing 2021’s revenue-price correlation. For those navigating high-volatility innovation, CollPlant’s ethical collagen edge in billion-dollar markets warrants close scrutiny.

Read full commentary →

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Latest News

News by impact score

Fine-tune

3 Sep

5 , 8:00 AM
CollPlant Biotechnologies completes acquisition of LightSolver and enters the photonic computing sector. Acquisition shifts CollPlant into photonic computing and redefines its competitive position.

31 Aug

5 , 8:00 AM
CollPlant Biotechnologies acquires LightSolver and enters supercomputing and photonic computing markets. Acquisition shifts CollPlant into supercomputing and photonic computing, redefining its core business and long-term trajectory.

13 Apr

3 PR Newswire, 7:00 AM
CollPlant Biotechnologies Ltd. (CLGN) issued a letter to shareholders outlining strategic updates, progress on clinical programs, financial position, and commitment to advancing plant-based collagen technology for regenerative medicine. CollPlant's shareholder letter delivers operational and strategic updates that may moderately influence investor sentiment and financial performance without fundamentally altering long-term trajectory.

26 Mar

4 PR Newswire, 8:30 AM
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) reported 2025 financial results and provided a corporate update. Financial results and corporate updates represent major strategic disclosures that significantly influence investor sentiment and company trajectory.

4 PR Newswire, 8:00 AM
CollPlant Biotechnologies reported its 2024 financial results, revealing a significant drop in revenues to $515,000 from $11 million in 2023, primarily due to a milestone payment from AbbVie in the previous year. The company announced promising six-month study data from its regenerative breast implant program, which aims to address a $3 billion market opportunity. CollPlant received a $2 million development payment from AbbVie and has expanded its distribution channels for its Vergenix STR product. The company also initiated a workforce reduction plan to optimize costs, reducing its workforce by approximately 20%. CollPlant's cash position remains supported by milestone payments and sales revenue, allowing continued operations into 2026. The announcement of significant advancements in product development and strategic collaborations indicates a likely substantial impact on future performance.

24 Mar

4 PR Newswire, 4:01 PM
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) received a Nasdaq notification for failing the minimum $1.00 bid price requirement after trading below it for 30 consecutive business days. The exchange grants 180 calendar days to regain compliance by achieving a $1.00 closing bid price for 10 consecutive business days. CollPlant plans to monitor its ADR price and consider remedies like a reverse stock split if needed. Nasdaq minimum bid deficiency notice creates delisting risk, significantly harming investor sentiment and stock trajectory.

26 Feb

3 PR Newswire, 8:00 AM
CollPlant Biotechnologies secures Korean patent allowance for its photocurable dermal filler, bolstering intellectual property protection in a key Asian market and supporting global commercialization efforts. Korean patent allowance for photocurable dermal filler strengthens IP portfolio and competitive positioning in Asia without fundamentally transforming core operations.

23 Feb

4 PR Newswire, 7:00 AM
CollPlant launches Ready-to-Print BioFlex, elevating its rhCollagen 3D bioprinting portfolio for advanced tissue engineering applications. Launch of ready-to-print BioFlex significantly expands CollPlant's bioprinting capabilities and market potential in regenerative medicine.

17 Feb

4 PR Newswire, 7:00 AM
CollPlant Biotechnologies Ltd. (CLGN) targets emerging aesthetic market fueled by GLP-1 weight-loss drugs like Ozempic, which cause skin laxity; company leverages rhCollagen platform for dermal fillers and regenerative skin treatments to address post-weight-loss sagging. CollPlant's strategic pivot to GLP-1-driven aesthetics market exploits booming demand for skin treatments, potentially boosting revenue and investor interest.

8 Feb

3 Simply Wall St., 7:45 AM
CollPlant Biotechnologies Ltd. is under scrutiny regarding its path to profitability. The company, which focuses on regenerative medicine and tissue repair, has yet to turn a profit despite its innovative product offerings. Investors are keenly watching for signs of financial improvement and strategic developments that could lead to a positive turnaround. The market remains cautious as the company navigates its growth challenges and seeks to establish a sustainable revenue model. The company's ongoing struggle for profitability and the potential for strategic developments may moderately influence its financial performance and market sentiment.

26 Nov

3 PR Newswire, 7:30 AM
CollPlant Biotechnologies Ltd. reported its financial results for the third quarter of 2025, highlighting key metrics and providing a corporate update. The company continues to focus on its innovative biotechnological solutions and strategic initiatives aimed at enhancing growth and market presence. The financial results and corporate update indicate moderate influences on the company's performance and market positioning.

13 Nov

3 Simply Wall St., 5:13 AM
CollPlant Biotechnologies Ltd. is facing concerns regarding its cash burn rate, which could impact its financial stability and operational capabilities. The company has been experiencing significant cash outflows, raising questions about its ability to sustain operations and fund future growth. Investors are advised to monitor the situation closely as it may affect market sentiment and the company's long-term prospects. The cash burn situation may moderately influence financial performance and investor sentiment, but other factors could balance the overall effect.

27 Oct

4 , 7:00 AM
CollPlant Biotechnologies Ltd. has expanded its distribution capabilities for rhCollagen in the United States and Canada, aiming to enhance market access and support its growth strategy. This expansion is expected to strengthen the company's position in the regenerative medicine market and improve its ability to meet customer demand. The expansion of distribution capabilities is a significant strategic move that could enhance market presence and investor sentiment.

20 Oct

4 PR Newswire, 7:00 AM
CollPlant Biotechnologies Ltd. announced that its rhCollagen-based BioInk outperformed Matrigel® in a study conducted by Technion - Israel Institute of Technology. The study highlights the potential of CollPlant's BioInk in regenerative medicine and tissue engineering applications, showcasing its advantages over traditional materials. The strong performance of rhCollagen-based BioInk in a reputable study could significantly enhance CollPlant's competitive position and market sentiment.

16 Oct

4 PR NewswireInsider MonkeyInsider MonkeyMT NewswiresBusiness Wire VideosWWDLifeMinute.TV Videos, 7:00 AM
Mayo Clinic researchers have developed a first-in-kind fully humanized 3D bioprinted human skin model using CollPlant's rhCollagen-based BioInk. This innovative model aims to enhance skin research and regenerative medicine, potentially leading to improved treatments for skin-related conditions and injuries. The development of a fully humanized 3D bioprinted skin model represents a significant advancement in regenerative medicine that could enhance CollPlant's product offerings and market position.

3 Oct

3 Simply Wall St., 6:47 AM
An insider at CollPlant Biotechnologies Ltd. increased their stake in the company over the past year, indicating potential confidence in its future performance. This move may reflect positive sentiment regarding the company's prospects and could influence market perception. Insider buying can signal confidence in the company's future, which may moderately influence market sentiment and performance.

30 Sep

4 PR Newswire, 7:00 AM
CollPlant Biotechnologies Ltd. announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler. The findings indicate potential advancements in the company's product offerings, which may enhance its position in the regenerative medicine market. Positive results from non-clinical studies could significantly impact product development and market positioning.

15 Sep

4 PR Newswire, 7:00 AM
CollPlant Biotechnologies Ltd. has expanded the distribution of its VergenixSTR product across Europe, enhancing its market presence and accessibility. This strategic move aims to increase the availability of its innovative regenerative medicine solutions, targeting a broader range of healthcare providers and patients in the region. Expanding distribution of a key product is likely to significantly impact market performance and investor sentiment.

2 Sep

3 , 7:00 AM
CollPlant Biotechnologies Ltd. will present at the 2025 International Conference on Biofabrication, showcasing its advancements in regenerative medicine and biofabrication technologies. The conference is expected to attract industry leaders and researchers, providing a platform for CollPlant to highlight its innovative solutions and potential collaborations. Participation in a significant conference can enhance visibility and networking opportunities, potentially influencing future collaborations and innovations.

20 Aug

3 , 7:00 AM
CollPlant Biotechnologies Ltd. reported its financial results for the second quarter of 2025, highlighting key metrics and providing a corporate update. The company continues to focus on its innovative biotechnological solutions, aiming to enhance its market position and drive growth in the upcoming quarters. The financial results and corporate update indicate moderate influences on the company's performance and market sentiment.

14 Jul

4 , 7:00 AM
CollPlant Biotechnologies Ltd. has appointed a new head of North America Commercial Operations, bringing in an expert in collagen biomaterials to lead the company's growth in the region. This strategic move aims to enhance the company's market presence and operational efficiency in North America, focusing on advancing its innovative collagen-based products. The appointment of a collagen biomaterials expert is a significant strategic move that could enhance market positioning and operational effectiveness.

9 Jun

4 PR Newswire, 7:00 AM
CollPlant Biotechnologies has expanded its collaboration with STEMCELL Technologies to include clinical development and commercial-scale manufacturing of its proprietary rhCollagen. This partnership aims to meet the evolving needs of the life sciences market and emphasizes the use of plant-derived materials as alternatives to animal-sourced options. CEO Yehiel Tal highlighted the commitment to advancing safer and sustainable solutions in regenerative medicine and aesthetics. The expanded collaboration with STEMCELL Technologies is a significant strategic move that could enhance product offerings and market positioning.

4 Jun

4 PR Newswire, 7:00 AM
CollPlant Biotechnologies has received a patent allowance from the European Patent and Trademark Office for its collagen-based injectable fillers and regenerative breast implants, targeting the aesthetic and reconstructive markets. The patent, effective until 2041, covers a 3D biocompatible soft tissue implant made from bioprinted scaffolds and injectable fillers using recombinant human collagen (rhCollagen). The global market for injectable fillers is estimated at over $6 billion, while the breast implant market exceeds $3 billion. CollPlant aims to lead in these markets by enhancing its intellectual property and developing safer, regenerative solutions for breast implants, addressing complications associated with current options. The patent allowance represents a significant strategic move that could enhance CollPlant's competitive position and market leadership in high-value sectors.

30 May

3 Simply Wall St., 8:05 AM
CollPlant Biotechnologies Ltd. focuses on 3D bioprinting and medical aesthetics, with a market cap of $38.95 million. The company reported first-quarter sales of $2.06 million, showing growth despite remaining unprofitable and facing challenges like high volatility and limited cash runway. CollPlant aims to secure strategic partnerships to improve its financial position amid industry changes. The company's growth in sales and focus on strategic partnerships may moderately influence its financial performance and market positioning.

3 , 7:00 AM
CollPlant Biotechnologies Ltd. announced a registered direct offering of $3.6 million, priced at-the-market under NASDAQ rules. The offering is expected to enhance the company's financial position and support its growth initiatives. The direct offering may provide necessary capital for growth but is not expected to significantly alter the company's overall trajectory.

29 May

3 , 6:33 AM
CollPlant Biotechnologies Ltd. reported its first quarter 2025 earnings, which fell short of market expectations. The company's financial performance showed a decline in revenue and increased operating losses, raising concerns among investors. Despite ongoing developments in its product pipeline, the disappointing results have led to a negative market reaction, impacting the stock price significantly. Earnings miss indicates potential challenges in financial performance and market sentiment.

28 May

3 , 7:00 AM
CollPlant Biotechnologies Ltd. reported its financial results for the first quarter of 2025, highlighting key metrics and developments in its operations. The company provided updates on its ongoing projects and strategic initiatives aimed at enhancing its market position and product offerings. The financial results and corporate updates indicate moderate influences on the company's performance and market sentiment.

8 May

4 Simply Wall St., 6:16 AM
CollPlant Biotechnologies (NASDAQ:CLGN) faces concerns over its cash burn, having a cash runway of only 10 months as of December 2024, with cash reserves of US$12m and a cash burn of US$15m. The company's cash burn increased by 292% in the last year, raising worries about its ability to fund growth. With a market capitalization of US$22m, the cash burn represents about 66% of its market value, indicating a high risk of dilution if new funds are needed. Overall, the increasing cash burn and short cash runway present significant challenges for the company. The significant increase in cash burn and limited cash runway could severely impact the company's future and performance.

15 Apr

4 PR Newswire, 8:00 AM
CollPlant Biotechnologies' rhCollagen BioInks align with the FDA's recent initiative to phase out animal testing for monoclonal antibody therapies and other drug candidates. The Collink.3D® BioInk products can be used for biofabrication of tissue-on-a-chip and organ-on-a-chip systems, offering a more economical and efficient alternative to traditional animal testing. CEO Yehiel Tal emphasized that these innovations support the FDA's New Approach Methodologies aimed at improving drug safety and reducing costs. Additionally, CollPlant's Computational Modeling and Simulation methodologies further minimize the need for animal studies in developing regenerative implants. The FDA's announcement indicates that animal testing may become the exception within 3-5 years, promoting ethical research practices and safer drugs. The FDA's plan to phase out animal testing represents a significant regulatory shift that could enhance CollPlant's market position and product relevance.

28 Mar

3 Simply Wall St., 6:45 AM
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) is nearing breakeven, with analysts predicting a final loss in 2025 before achieving profits of US$1.1m in 2026. The company, focused on 3D bioprinting and medical aesthetics, reported a loss of US$17m for the last financial year. Analysts expect an average annual growth rate of 57% to reach breakeven, which may be overly optimistic. CollPlant has no debt, reducing investment risk. For deeper insights, further analysis of the company's performance and management is suggested. The anticipated growth rate and path to profitability could moderately influence financial performance and market sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us